We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

OTC Markets OTCPK - Delayed Quote USD

Ascletis Pharma Inc. (ASCLF)

0.8144

0.0000

(0.00%)

At close: May 5 at 4:00:00 PM EDT

Key Events

Loading Chart for ASCLF

Previous Close 0.0000
Open 0.9285
Bid 0.8051 x --
Ask 0.8851 x --
Day's Range 0.9285 - 0.9285
52 Week Range 0.1402 - 1.2000
Volume 200
Avg. Volume 556
Market Cap (intraday) 813.364M
Beta (5Y Monthly) 0.33
PE Ratio (TTM) --
EPS (TTM) -0.0400
Earnings Date Mar 26, 2025
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

www.ascletis.com

231

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial

Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

ASCLF

240.33%

HANG SENG INDEX (^HSI)

12.97%

1-Year Return

ASCLF

302.57%

HANG SENG INDEX (^HSI)

21.98%

3-Year Return

ASCLF

51.69%

HANG SENG INDEX (^HSI)

13.30%

5-Year Return

ASCLF

146.79%

HANG SENG INDEX (^HSI)

6.11%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Ascletis Pharma Inc.

0.8144

0.00%

Mkt Cap 813.364M

Industry Biotechnology

0.4400

-9.28%

Mkt Cap EUR 132.235M

Industry Biotechnology

Xenon Pharmaceuticals Inc.

37.54

-1.93%

Mkt Cap 2.875B

Industry Biotechnology

Minerva Neurosciences, Inc.

1.7100

0.00%

Mkt Cap 11.959M

Industry Biotechnology

Centessa Pharmaceuticals plc

13.57

-0.29%

Mkt Cap 1.807B

Industry Biotechnology

Praxis Precision Medicines, Inc.

38.96

-3.18%

Mkt Cap 793.576M

Industry Biotechnology

DBV Technologies S.A.

9.25

+3.35%

Mkt Cap 252.929M

Industry Biotechnology

15.11

-10.96%

Mkt Cap 215.5M

Industry Biotechnology

Vera Therapeutics, Inc.

25.53

+0.87%

Mkt Cap 1.628B

Industry Biotechnology

Design Therapeutics, Inc.

4.3600

-6.24%

Mkt Cap 247.512M

Industry Biotechnology

Kymera Therapeutics, Inc.

33.58

-4.82%

Mkt Cap 2.187B

Industry Biotechnology

Valuation Measures

    Annual 

As of 5/5/2025

Market Cap

813.30M
Enterprise Value

546.56M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

4.62k
Price/Book (mrq)

2.90
Enterprise Value/Revenue

3.10k
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-10.96%
Return on Equity (ttm)

-13.97%
Revenue (ttm)

1.28M
Net Income Avi to Common (ttm)

-300.94M
Diluted EPS (ttm)

-0.0400

Balance Sheet and Cash Flow

Total Cash (mrq)

1.95B
Total Debt/Equity (mrq)

0.39%
Levered Free Cash Flow (ttm)

-208.35M

VBIZF Viva Biotech Holdings

0.2270

0.00%

PTCHF PureTech Health plc

1.6500

0.00%

IVBXF Innovent Biologics, Inc.

6.88

0.00%

PHGUF Pharming Group N.V.

0.9130

0.00%

IUGNF Imugene Limited

0.0189

+5.00%

MEOBF Mesoblast Limited

1.4400

0.00%

ELVAF Evolva Holding SA

0.9000

0.00%

CSPHF CStone Pharmaceuticals

0.5180

0.00%

BITRF Biotron Limited

0.0027

0.00%

WXIBF WuXi Biologics (Cayman) Inc.

3.0000

0.00%

SBMFF Sino Biopharmaceutical Limited

0.4940

0.00%

SYGGF Synairgen plc

0.0010

0.00%

MLLCF Molecular Partners AG

4.2200

0.00%

INRLF Valneva SE

3.2700

0.00%

CASBF CanSino Biologics Inc.

3.2000

0.00%

MAYNF Mayne Pharma Group Limited

3.9500

0.00%